Elicio Therapeutics (ELTX) Gross Margin (2020 - 2021)
Elicio Therapeutics posted quarterly Gross Margin of 98.28% for Q4 2021, down 738.0% year-on-year from 15.4% in Q4 2020, and down 1.72% on a QoQ basis from 100.0% in Q3 2021.
Elicio Therapeutics (ELTX) has 2 years of Gross Margin data on file, last reported at 98.28% in Q4 2021.
- For the quarter ending Q4 2021, Gross Margin fell 738.0% year-over-year to 98.28%; the trailing twelve-month figure through Dec 2021 stood at 98.43% (down 17866.0% YoY), and the FY2022 full-year result was 100.0%, up 157.0% from the prior year.
- Gross Margin for Q4 2021 stood at 98.28%, down from 100.0% in the prior quarter.
- Across five years, Gross Margin topped out at 105.66% in Q4 2020 and bottomed at 54.32% in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 98.28% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 100.00% |
| Mar 31, 2021 | 100.00% |
| Dec 31, 2020 | 105.66% |
| Sep 30, 2020 | 57.92% |
| Jun 30, 2020 | 54.32% |